PTCT SEC Filing News — PTC Therapeutics, Inc.

Latest SEC filings for PTC Therapeutics, Inc. (PTCT) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-16.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spi…
Sector: Healthcare Industry: Biotechnology Market Cap: $5.1B
20
Total Filings
0
Bullish Classifications
10
Bearish Classifications
10
Insider Transactions
2
Material Events (8-K)
0
Periodic Reports
Rule-based classifications for PTCT currently lean bearish. Of the 20 filing records displayed, 10 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
PTCT Filing Activity Snapshot 2026-08-17 — 2026-10-16
Insider Transactions (Form 4)
0 buys vs 10 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$3.65M
Michael Schmertzler · 2026-08-19
50,000 shares · Form 144
Form 144 Notices
8
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 10 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 10 filings in this group are Form 4s for PTC Therapeutics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 10 insider filings shown, the breakdown is 10 open-market sale. 10 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×10
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Form 4 Open-market sale Insider Selling 2026-10-16

PTCT insider SCHMERTZLER MICHAEL (Director) sold 2,500 shares (~$149.0K)

SCHMERTZLER MICHAEL, listed as Director at PTC THERAPEUTICS, INC., reported an open-market sale of 2,500 PTCT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 2,118 $59.52 $126.1K
S Open-market sale 382 $60.14 $23.0K
Filing: Form 4 (Insider Transaction) Insider: SCHMERTZLER MICHAEL (Director) Shares: 2,500 Est. Value: $149.0K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-13

PTCT insider Boulding Mark Elliott (EXEC. VP AND CLO) sold 192 shares (~$12.3K)

Boulding Mark Elliott, listed as EXEC. VP AND CLO at PTC THERAPEUTICS, INC., reported an open-market sale of 192 PTCT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 192 $39.42 $7.6K
S Open-market sale 192 $64.26 $12.3K
M Option exercise derivative · Stock Option (Right to Buy) 192 — —
Filing: Form 4 (Insider Transaction) Insider: Boulding Mark Elliott (EXEC. VP AND CLO) Shares: 192 Est. Value: $12.3K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-09

PTCT insider SCHMERTZLER MICHAEL (Director) sold 2,500 shares (~$158.5K)

SCHMERTZLER MICHAEL, listed as Director at PTC THERAPEUTICS, INC., reported an open-market sale of 2,500 PTCT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 2,447 $63.38 $155.1K
S Open-market sale 53 $63.95 $3.4K
Filing: Form 4 (Insider Transaction) Insider: SCHMERTZLER MICHAEL (Director) Shares: 2,500 Est. Value: $158.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-07

PTCT insider Boulding Mark Elliott (EXEC. VP AND CLO) sold 2,073 shares (~$132.8K)

Boulding Mark Elliott, listed as EXEC. VP AND CLO at PTC THERAPEUTICS, INC., reported an open-market sale of 2,073 PTCT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 1,638 $39.42 $64.6K
S Open-market sale 1,638 $64.03 $104.9K
M Option exercise 435 $39.42 $17.1K
S Open-market sale 435 $64.16 $27.9K
M Option exercise derivative · Stock Option (Right to Buy) 1,638 — —
M Option exercise derivative · Stock Option (Right to Buy) 435 — —
Filing: Form 4 (Insider Transaction) Insider: Boulding Mark Elliott (EXEC. VP AND CLO) Shares: 2,073 Est. Value: $132.8K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-02

PTCT insider STEELE GLENN JR MD PHD (Director) sold 12,000 shares (~$781.9K)

STEELE GLENN JR MD PHD, listed as Director at PTC THERAPEUTICS, INC., reported an open-market sale of 12,000 PTCT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 12,000 $11.23 $134.8K
S Open-market sale 12,000 $65.16 $781.9K
M Option exercise derivative · Stock Option (Right to Buy) 12,000 — —
Filing: Form 4 (Insider Transaction) Insider: STEELE GLENN JR MD PHD (Director) Shares: 12,000 Est. Value: $781.9K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-18

PTCT insider SCHMERTZLER MICHAEL (Director) sold 20,000 shares (~$1.35M)

SCHMERTZLER MICHAEL, listed as Director at PTC THERAPEUTICS, INC., reported an open-market sale of 20,000 PTCT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 2,994 $66.58 $199.3K
S Open-market sale 7,006 $67.35 $471.9K
S Open-market sale 9,624 $67.83 $652.8K
S Open-market sale 376 $68.45 $25.7K
Filing: Form 4 (Insider Transaction) Insider: SCHMERTZLER MICHAEL (Director) Shares: 20,000 Est. Value: $1.35M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-11

PTCT insider SCHMERTZLER MICHAEL (Director) sold 20,000 shares (~$1.35M)

SCHMERTZLER MICHAEL, listed as Director at PTC THERAPEUTICS, INC., reported an open-market sale of 20,000 PTCT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 9,428 $67.79 $639.1K
S Open-market sale 572 $68.67 $39.3K
S Open-market sale 10,000 $67.34 $673.4K
Filing: Form 4 (Insider Transaction) Insider: SCHMERTZLER MICHAEL (Director) Shares: 20,000 Est. Value: $1.35M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-28

PTCT insider SCHMERTZLER MICHAEL (Director) sold 25,000 shares (~$1.81M)

SCHMERTZLER MICHAEL, listed as Director at PTC THERAPEUTICS, INC., reported an open-market sale of 25,000 PTCT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 6,874 $72.74 $500.0K
S Open-market sale 5,626 $73.18 $411.7K
S Open-market sale 11,890 $71.55 $850.7K
S Open-market sale 610 $72.22 $44.1K
Filing: Form 4 (Insider Transaction) Insider: SCHMERTZLER MICHAEL (Director) Shares: 25,000 Est. Value: $1.81M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-21

PTCT insider SCHMERTZLER MICHAEL (Director) sold 25,000 shares (~$1.81M)

SCHMERTZLER MICHAEL, listed as Director at PTC THERAPEUTICS, INC., reported an open-market sale of 25,000 PTCT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 5,335 $72.86 $388.7K
S Open-market sale 7,165 $73.67 $527.8K
S Open-market sale 9,419 $70.78 $666.7K
S Open-market sale 2,390 $71.88 $171.8K
S Open-market sale 691 $72.92 $50.4K
Filing: Form 4 (Insider Transaction) Insider: SCHMERTZLER MICHAEL (Director) Shares: 25,000 Est. Value: $1.81M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-19

PTCT insider Boulding Mark Elliott (EXEC. VP AND CLO) sold 2,813 shares (~$204.1K)

Boulding Mark Elliott, listed as EXEC. VP AND CLO at PTC THERAPEUTICS, INC., reported an open-market sale of 2,813 PTCT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 2,813 $25.69 $72.3K
S Open-market sale 1,844 $72.39 $133.5K
S Open-market sale 969 $72.90 $70.6K
M Option exercise derivative · Stock Option (Right to Buy) 2,813 — —
Filing: Form 4 (Insider Transaction) Insider: Boulding Mark Elliott (EXEC. VP AND CLO) Shares: 2,813 Est. Value: $204.1K
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 8 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. PTC Therapeutics, Inc. has 8 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-10-09

PTCT Form 144 filed for proposed insider sale by Boulding Mark Elliott (192 shares) ~$12.3K

Boulding Mark Elliott filed a Form 144 with the SEC indicating intent to sell PTCT (PTC THERAPEUTICS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Boulding Mark Elliott Shares: 192 Est. Value: $12.3K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-10-07

PTCT Form 144 filed for proposed insider sale by Section Six Partners, L.P. (10,000 shares) ~$643.5K

Section Six Partners, L.P. filed a Form 144 with the SEC indicating intent to sell PTCT (PTC THERAPEUTICS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Section Six Partners, L.P. Shares: 10,000 Est. Value: $643.5K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-10-06

PTCT Form 144 filed for proposed insider sale by Boulding Mark Elliott (435 shares) ~$27.9K

Boulding Mark Elliott filed a Form 144 with the SEC indicating intent to sell PTCT (PTC THERAPEUTICS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Boulding Mark Elliott Shares: 435 Est. Value: $27.9K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-10-05

PTCT Form 144 filed for proposed insider sale by Boulding Mark Elliott (1,638 shares) ~$104.9K

Boulding Mark Elliott filed a Form 144 with the SEC indicating intent to sell PTCT (PTC THERAPEUTICS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Boulding Mark Elliott Shares: 1,638 Est. Value: $104.9K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-30

PTCT Form 144 filed for proposed insider sale by STEELE GLENN JR MD PHD (12,000 shares) ~$781.9K

STEELE GLENN JR MD PHD filed a Form 144 with the SEC indicating intent to sell PTCT (PTC THERAPEUTICS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: STEELE GLENN JR MD PHD Shares: 12,000 Est. Value: $781.9K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-09

PTCT Form 144 filed for proposed insider sale by Section Six Partners, L.P. (40,000 shares) ~$2.74M

Section Six Partners, L.P. filed a Form 144 with the SEC indicating intent to sell PTCT (PTC THERAPEUTICS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Section Six Partners, L.P. Shares: 40,000 Est. Value: $2.74M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-19

PTCT Form 144 filed for proposed insider sale by Michael Schmertzler (50,000 shares) ~$3.65M

Michael Schmertzler filed a Form 144 with the SEC indicating intent to sell PTCT (PTC THERAPEUTICS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Michael Schmertzler Shares: 50,000 Est. Value: $3.65M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-17

PTCT Form 144 filed for proposed insider sale by Boulding Mark Elliott (2,813 shares) ~$201.7K

Boulding Mark Elliott filed a Form 144 with the SEC indicating intent to sell PTCT (PTC THERAPEUTICS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Boulding Mark Elliott Shares: 2,813 Est. Value: $201.7K
View on SEC EDGAR → Open Filing Document →
Material Events 2 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 2 in this period for PTC Therapeutics, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-21

PTCT filed 8-K — material company event

PTC THERAPEUTICS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-08-28

PTCT filed 8-K — material company event

PTC THERAPEUTICS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →

How we classify PTC Therapeutics, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on PTCT. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — PTCT SEC Filings

More Tools for PTCT

PTCT Full Stock Analysis PTCT Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper PTCT analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the PTCT stock analysis page.

PTCT Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer